{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:13:01Z","timestamp":1791573181844,"version":"4.3.4"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Triple-negative breast cancer (TNBC) with bone metastasis is challenging to treat due to an immunosuppressive microenvironment and the limited, transient immune activation from conventional external beam radiotherapy. Inducing immunogenic cell death (ICD) offers a strategy to remodel this environment, but its systemic effects remain to be validated. Here, we investigate iodine-125 (\n                      <jats:sup>125<\/jats:sup>\n                      I) brachytherapy as a method to induce sustained ICD and activate systemic antitumor immunity in TNBC bone metastasis using transcriptomic analysis, a dual-tumor model, and CALR-targeted molecular imaging.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A dual-tumor model of 4T1 mouse breast cancer with tibial bone metastasis and distal subcutaneous implantation was established. The therapeutic efficacy of\n                      <jats:sup>\u00b9\u00b2\u2075<\/jats:sup>\n                      I seeds at different doses (0.3-0.8 mCi), alone or in combination with anti\u2013PD-L1 antibody, was systematically assessed. ICD biomarkers (CALR, HMGB1) and immune cell infiltration were analyzed using Western blot, qRT-PCR, immunohistochemistry, and flow cytometry. Transcriptome sequencing was performed to explore changes in ICD and related immune pathways. In vivo dynamic imaging of ICD was achieved using a CALR-targeting bimodal nanoprobe. Comparative analyses were conducted between\n                      <jats:sup>125<\/jats:sup>\n                      I brachytherapy and EBRT to assess differences in tumor control and immune activation. Treatment sequencing studies were performed to evaluate the optimal combination strategy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      This study confirmed that\n                      <jats:sup>125<\/jats:sup>\n                      I seeds effectively induce sustained immunogenic cell death, significantly upregulating damage-associated molecular patterns (DAMPs) such as CALR and HMGB1. In the 4T1 bone metastasis model, local implantation of\n                      <jats:sup>125<\/jats:sup>\n                      I (0.3-0.8 mCi) inhibited tumor growth in a dose-dependent manner, with the 0.8 mCi group showing the best therapeutic effect and no significant toxicity. Mechanistically,\n                      <jats:sup>125<\/jats:sup>\n                      I promoted CD8\u03b1\u207aT cell infiltration, activated ICD-related pathways, and triggered systemic antitumor immunity, as demonstrated by inhibition of distant tumor growth in the bilateral tumor system. Compared with EBRT, 125I brachytherapy achieved superior local control and more robust immune activation. Using a CALR-targeting nanoprobe, dynamic\n                      <jats:italic>in vivo<\/jats:italic>\n                      imaging of ICD was successfully achieved. Treatment sequencing studies revealed that initiating with\n                      <jats:sup>125<\/jats:sup>\n                      I brachytherapy followed by combination therapy with PD-L1 antibody and Abraxane resulted in the most favorable outcome, confirming this \u201c\n                      <jats:sup>125<\/jats:sup>\n                      I-first\u201d approach as an effective immune priming strategy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>\n                      This study demonstrates that\n                      <jats:sup>125<\/jats:sup>\n                      I brachytherapy overcomes the limitations of conventional radiotherapy by inducing sustained immunogenic cell death, remodeling the tumor immune microenvironment, and activating systemic antitumor immunity.\n                      <jats:sup>125<\/jats:sup>\n                      I seeds not only inhibit the growth of TNBC bone metastases and distal tumors but also significantly enhance the infiltration of CD8\u03b1\n                      <jats:sup>\u207a<\/jats:sup>\n                      T cells into tumor sites. Notably, the sequential regimen of\n                      <jats:sup>125<\/jats:sup>\n                      I brachytherapy followed by PD-L1 antibody and Abraxane shows significant synergistic effects. These findings establish\n                      <jats:sup>125<\/jats:sup>\n                      I brachytherapy as a superior immune-priming modality and provide a mechanistic rationale for integrating low-dose-rate brachytherapy with immunotherapy to overcome resistance in bone-metastatic TNBC, offering strong potential for clinical translation., iodine-125 seeds, triple-negative breast cancer.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1761538","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T05:33:49Z","timestamp":1774935229000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Iodine-125 brachytherapy triggers immunogenic cell death and potentiates anti-PD-L1 immunotherapy in bone metastatic triple-negative breast cancer"],"prefix":"10.3389","volume":"17","author":[{"given":"Min","family":"Li","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University","place":["Xi\u2019an, Shanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, The 960th Hospital of the People's Liberation Army (PLA)","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, The 960th Hospital of the People's Liberation Army (PLA)","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiyu","family":"Sun","sequence":"additional","affiliation":[{"name":"Jinzhou Medical University Graduate Training Base (The 960th Hospital of the PLA)","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanbo","family":"Hu","sequence":"additional","affiliation":[{"name":"Jinzhou Medical University Graduate Training Base (The 960th Hospital of the PLA)","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, The 960th Hospital of the People's Liberation Army (PLA)","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihao","family":"Li","sequence":"additional","affiliation":[{"name":"Shandong University of Traditional Chinese Medicine Graduate Training Base (The 960th Hospital of the People's Liberation Army (PLA))","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyang","family":"Han","sequence":"additional","affiliation":[{"name":"Shandong Second Medical University Graduate Training Base (The 960th Hospital of the People's Liberation Army (PLA))","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Jinzhou Medical University Graduate Training Base (The 960th Hospital of the PLA)","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiageng","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, The 960th Hospital of the People's Liberation Army (PLA)","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengsong","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, The 960th Hospital of the People's Liberation Army (PLA)","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The 960th Hospital of the People's Liberation Army (PLA)","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University","place":["Xi\u2019an, Shanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.critrevonc.2017.04.008","article-title":"Systematic review and meta-analysis on the proportion of patients with breast cancer who develop bone metastases","volume":"115","author":"Body","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s40425-019-0793-8","article-title":"Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer","volume":"7","author":"Landi","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2023.08.008","article-title":"Bone-targeted therapy regimen and skeletal-related events in patients surviving longer than 2 years with metastatic breast cancer and bone metastasis","volume":"23","author":"Jayan","year":"2023","journal-title":"Clin Breast Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2147\/itt.s495751","article-title":"Recent advances in immune checkpoint inhibitors for triple-negative breast cancer","volume":"14","author":"Corti","year":"2025","journal-title":"Immunotargets Ther"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/s1470-2045(19)30689-8","article-title":"Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Schmid","year":"2020","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.4161\/onci.21990","article-title":"Myeloid-derived suppressor cells expand during breast cancer progression and promote tumor-induced bone destruction","volume":"1","author":"Danilin","year":"2012","journal-title":"Oncoimmunology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2022.03.006","article-title":"Bone metastasis attenuates efficacy of immune checkpoint inhibitors and displays \"cold\" immune characteristics in non-small cell lung cancer","volume":"166","author":"Zhu","year":"2022","journal-title":"Lung Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/biom11111643","article-title":"The role of TGF-\u03b2 in bone metastases","volume":"11","author":"Trivedi","year":"2021","journal-title":"Biomolecules"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-07-0234","article-title":"Molecular biology of bone metastasis","volume":"6","author":"Kingsley","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2020.06.004","article-title":"Hypoxia in bone metastasis and osteolysis","volume":"489","author":"Todd","year":"2020","journal-title":"Cancer Lett"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1172\/jci143764","article-title":"Exploiting bone niches: progression of disseminated tumor cells to metastasis","volume":"131","author":"Muscarella","year":"2021","journal-title":"J Clin Invest"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1074477","article-title":"Radiotherapy induced immunogenic cell death by remodeling tumor immune microenvironment","volume":"13","author":"Zhu","year":"2022","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.semcancer.2023.11.006","article-title":"Tumor hypoxia and radiotherapy: a major driver of resistance even for novel radiotherapy modalities","volume":"98","author":"Beckers","year":"2024","journal-title":"Semin Cancer Biol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16613","article-title":"ROS and radiotherapy: more we care","volume":"8","author":"Sonveaux","year":"2017","journal-title":"Oncotarget"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4143\/crt.2024.255","article-title":"Role of HIF-1\u03b1 in the responses of tumors to radiotherapy and chemotherapy","volume":"57","author":"Song","year":"2025","journal-title":"Cancer Res Treat"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2021.155709","article-title":"TGF-beta signaling in cancer radiotherapy","volume":"148","author":"Wang","year":"2021","journal-title":"Cytokine"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2024.04.018","article-title":"External beam radiation therapy for palliation of symptomatic bone metastases: an ASTRO clinical practice guideline","volume":"14","author":"Alcorn","year":"2024","journal-title":"Pract Radiat Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.23736\/s0390-5616.20.05060-2","article-title":"Radiation dose-escalation and dose-fractionation modulate the immune microenvironment, cancer stem cells and vasculature in experimental high-grade gliomas","volume":"67","author":"Riva","year":"2023","journal-title":"J Neurosurg Sci"},{"key":"B21","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s10142-024-01392-1","article-title":"Iodine-125 seed inhibits proliferation and promotes apoptosis of cholangiocarcinoma cells by inducing the ROS\/p53 axis","volume":"24","author":"Kang","year":"2024","journal-title":"Funct Integr Genomics"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2018.6","article-title":"Using immunotherapy to boost the abscopal effect","volume":"18","author":"Ngwa","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.114231","article-title":"Bilayer nanofiber-coated stent integrating internal radiation and spatiotemporal IL-12 release promotes antitumor immune response","volume":"387","author":"Qin","year":"2025","journal-title":"J Control Release"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.4161\/onci.28518","article-title":"Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death","volume":"3","author":"Golden","year":"2014","journal-title":"Oncoimmunology"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1177\/1758834017742575","article-title":"Radiation effects on antitumor immune responses: current perspectives and challenges","volume":"10","author":"Walle","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1101855","article-title":"Depletion of plasmacytoid dendritic cells inhibits tumor growth and prevents bone metastasis of breast cancer cells","volume":"189","author":"Sawant","year":"2012","journal-title":"J Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10040560","article-title":"Anti-Gr-1 antibody provides short-term depletion of MDSC in lymphodepleted mice with active-specific melanoma therapy","volume":"10","author":"Rose","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a022301","article-title":"Targeting TGF-\u03b2 signaling for therapeutic gain","volume":"9","author":"Akhurst","year":"2017","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","article-title":"Therapeutic cancer vaccines: advancements, challenges, and prospects","volume":"8","author":"Fan","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-14-1258","article-title":"Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade","volume":"74","author":"Dovedi","year":"2014","journal-title":"Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.21417\/b7h34s","article-title":"Radiotherapy and CTLA-4 blockade shape the TCR repertoire of tumor-infiltrating T cells","volume":"6","author":"Rudqvist","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat Commun"},{"key":"B33","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s00262-024-03934-9","article-title":"Hypofractionated radiotherapy combined with a PD-1 inhibitor, granulocyte macrophage-colony stimulating factor, and thymosin-\u03b11 in advanced metastatic solid tumors: a multicenter phase II clinical trial","volume":"74","author":"Yu","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02230-0","article-title":"Immunogenic hypofractionated radiotherapy sensitising head and neck squamous cell carcinoma to anti-PD-L1 therapy in MDSC-dependent manner","volume":"128","author":"Mao","year":"2023","journal-title":"Br J Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00229","article-title":"Barriers to radiation-induced in situ tumor vaccination","volume":"8","author":"Wennerberg","year":"2017","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1771355","article-title":"Synergistic effects of radiotherapy and immunotherapy: improving oncological outcomes","volume":"17","author":"Chen","year":"2026","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13045-025-01678-2","article-title":"Anti-TGF-\u03b2\/PD-L1 bispecific antibody synergizes with radiotherapy to enhance antitumor immunity and mitigate radiation-induced pulmonary fibrosis","volume":"18","author":"Wu","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-23-0903","article-title":"A bifunctional antibody targeting PD-1 and TGF-\u03b2 signaling has antitumor activity in combination with radiotherapy and attenuates radiation-induced lung injury","volume":"13","author":"Wang","year":"2025","journal-title":"Cancer Immunol Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.2007","article-title":"Development and verification of a novel immunogenic cell death-related signature for predicting the prognosis and immune infiltration in triple-negative breast cancer","volume":"7","author":"Li","year":"2024","journal-title":"Cancer Rep (Hoboken)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.22541\/au.169025407.77748111\/v1","article-title":"Pan-cancer analyses of immunogenic cell death-derived gene signatures: potential biomarkers for prognosis and immunotherapy","volume":"7","author":"Han","year":"2024","journal-title":"Cancer Rep (Hoboken)"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.4103","article-title":"Abscopal effect of radiotherapy in the immunotherapy era: systematic review of reported cases","volume":"11","author":"Dagoglu","year":"2019","journal-title":"Cureus"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdac132","article-title":"The abscopal effect: systematic review in patients with brain and spine metastases","volume":"4","author":"Pangal","year":"2022","journal-title":"Neuro-Oncol Adv"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222011061","article-title":"The abscopal effect: a review of pre-clinical and clinical advances","volume":"22","author":"Janopaul-Naylor","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/8970173","article-title":"Immune checkpoint inhibitor therapy for bone metastases: specific microenvironment and current situation","volume":"2021","author":"Liu","year":"2021","journal-title":"J Immunol Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3390\/ph17121591","article-title":"Immunotherapy in the battle against bone metastases: mechanisms and emerging treatments","volume":"6","author":"Hamza","year":"2024","journal-title":"Pharm (Basel)"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1769063","article-title":"Atezolizumab in the treatment of metastatic triple-negative breast cancer","volume":"20","author":"P\u00e9rez-Garc\u00eda","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2023.100505","article-title":"Immune checkpoint inhibitors in bone metastasis: clinical challenges, toxicities, and mechanisms","volume":"43","author":"Joseph","year":"2023","journal-title":"J Bone Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s00590-024-04018-1","article-title":"Response rate specific to bone metastasis of various cancers for immune checkpoint inhibitors: a systematic review","volume":"34","author":"Tsukamoto","year":"2024","journal-title":"Eur J Orthop Surg Traumatol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"22397","DOI":"10.1038\/s41598-022-27048-3","article-title":"Phase Ib\/II study of nivolumab combined with palliative radiation therapy for bone metastasis in patients with HER2-negative metastatic breast cancer","volume":"12","author":"Takada","year":"2022","journal-title":"Sci Rep"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abg0117","article-title":"Sequence of \u03b1PD-1 relative to local tumor irradiation determines the induction of abscopal antitumor immune responses","volume":"6","author":"Wei","year":"2021","journal-title":"Sci Immunol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"7709","DOI":"10.1038\/s41467-023-43462-1","article-title":"Low-dose radiotherapy combined with dual PD-L1 and VEGFA blockade elicits antitumor response in hepatocellular carcinoma mediated by activated intratumoral CD8(+) exhausted-like T cells","volume":"14","author":"Li","year":"2023","journal-title":"Nat Commun"},{"key":"B52","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.ccell.2025.02.010","article-title":"Low-dose irradiation of the gut improves the efficacy of PD-L1 blockade in metastatic cancer patients","volume":"43","author":"Chen","year":"2025","journal-title":"Cancer Cell"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1761538\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T05:33:51Z","timestamp":1774935231000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1761538\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":52,"alternative-id":["10.3389\/fimmu.2026.1761538"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1761538","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"article-number":"1761538"}}